StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
19
This year
2
Publishing Date
2024 - 03 - 22
1
2024 - 01 - 31
1
2023 - 09 - 18
1
2023 - 08 - 15
1
2023 - 07 - 24
1
2023 - 03 - 31
1
2023 - 01 - 30
1
2022 - 09 - 19
1
2022 - 06 - 24
1
2022 - 04 - 22
1
2022 - 04 - 01
1
2022 - 03 - 25
3
2021 - 10 - 11
1
2021 - 09 - 16
1
2021 - 07 - 08
1
2021 - 06 - 02
1
2021 - 03 - 23
1
Sector
Health technology
19
Tags
America
67
Antibody
13
Application
12
Approval
21
Biosimilar
39
Breast
13
Cancer
106
Covid
17
Covid-19
12
Device
14
Diabetes
18
Diagnostics
19
Disease
76
Drug
115
Drug delivery
11
Earnings
21
Europe
17
Expansion
11
Expected
35
Eye
21
Fda
28
Financial
24
Financial results
13
Gene therapy
11
Global
229
Growing
47
Growth
262
Health
19
Immunotherapy
12
Kisqali
11
Leukemia
12
Liver
20
Market
599
N/a
1115
Novartis
133
Patent
13
People
20
Pharma
17
Pharmaceuticals
17
Pipeline
12
Positive
19
Potential
13
Reach
34
Report
195
Research
129
Respiratory
15
Results
52
Risk
11
Sales
11
Sclerosis
13
Set
16
Study
17
T-cell
12
Technology
14
Therapeutics
114
Therapy
89
Treatment
137
Trial
25
Vaccine
16
Year
12
Entities
Amgen inc.
1
Incyte corporation
1
Novartis ag
19
Symbols
ABBV
31
ADIL
10
ALNY
19
ALPMF
14
ALPMY
14
AMGN
14
ANVS
10
AQST
18
ARVL
21
AZN
13
BBIO
16
BGNE
19
BIIB
13
BMY
27
BNTX
17
BYSI
11
CHRS
21
CLDX
10
CLSD
15
DARE
13
FBIO
10
FNCTF
21
GILD
13
GSK
12
HOTH
14
IMMP
11
IMMX
10
INCY
15
IONS
21
IT
12
JNJ
46
LLY
30
LTUM
14
MDWD
11
MRK
19
MS
10
MYOV
10
NDAQ
42
NVS
19
NVSEF
15
PFE
45
PLRX
10
PPRUF
11
PPRUY
11
RCKT
11
RDHL
10
REGN
26
RGNX
17
RNAZ
10
SCYX
11
SLS
11
SNY
103
SNYNF
79
SRNE
19
TAK
14
TAYD
17
TEVJF
14
TNXP
12
VERU
10
VRTX
11
Exchanges
Nasdaq
15
Nyse
19
Crawled Date
2024 - 03 - 22
1
2024 - 01 - 31
1
2023 - 09 - 18
1
2023 - 08 - 15
1
2023 - 07 - 24
1
2023 - 03 - 31
1
2023 - 01 - 30
1
2022 - 09 - 19
1
2022 - 06 - 24
1
2022 - 04 - 22
1
2022 - 04 - 01
1
2022 - 03 - 25
3
2021 - 10 - 11
1
2021 - 09 - 16
1
2021 - 07 - 08
1
2021 - 06 - 02
1
2021 - 03 - 23
1
Crawled Time
06:00
7
07:00
2
08:00
1
12:00
3
12:20
2
14:00
2
16:00
1
23:00
1
Source
www.biospace.com
2
www.globenewswire.com
17
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Positive
symbols :
Nvs
save search
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published:
2024-03-22
(Crawled : 12:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
-3.12%
|
O:
0.17%
H:
0.28%
C:
-0.01%
fabhalta
first
chmp
positive
novartis
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Published:
2024-01-31
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
-13.61%
|
O:
-2.04%
H:
0.19%
C:
-1.97%
sales
year
momentum
positive
innovation
novartis
growth
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published:
2023-09-18
(Crawled : 06:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
9.62%
|
O:
-0.05%
H:
0.0%
C:
-1.31%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
-9.31%
|
O:
0.06%
H:
0.09%
C:
-0.6%
biosimilar
chmp
breast
positive
cancer
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Published:
2023-08-15
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
-9.95%
|
O:
-0.32%
H:
0.18%
C:
-0.44%
biosimilar
positive
results
study
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Published:
2023-07-24
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
-11.36%
|
O:
-0.05%
H:
0.24%
C:
-0.83%
biosimilar
chmp
positive
sclerosis
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
Published:
2023-03-31
(Crawled : 12:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
24.64%
|
O:
-0.95%
H:
2.14%
C:
2.14%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
1.64%
|
O:
0.22%
H:
0.45%
C:
0.24%
chmp
positive
novartis
heart
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published:
2023-01-30
(Crawled : 07:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
24.85%
|
O:
0.0%
H:
0.0%
C:
0.0%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
4.01%
|
O:
0.65%
H:
0.37%
C:
-0.48%
biosimilar
chmp
positive
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published:
2022-09-19
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
15.41%
|
O:
-0.52%
H:
0.69%
C:
0.62%
AMGN
|
$262.77
-0.49%
-0.49%
2M
|
Health Technology
|
15.49%
|
O:
-0.22%
H:
0.1%
C:
0.05%
biosimilar
trial
positive
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published:
2022-06-24
(Crawled : 12:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
42.6%
|
O:
6.71%
H:
0.0%
C:
-0.1%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
14.09%
|
O:
2.38%
H:
0.0%
C:
0.0%
scemblix
treatment
chmp
novartis
leukemia
positive
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
Published:
2022-04-22
(Crawled : 14:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
2.29%
|
O:
-0.6%
H:
0.0%
C:
0.0%
tabrecta
chmp
novartis
positive
cancer
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Published:
2022-04-01
(Crawled : 16:00)
- biospace.com/
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
6.07%
|
O:
-0.64%
H:
0.6%
C:
0.57%
immunology
trial
positive
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published:
2022-03-25
(Crawled : 14:00)
- biospace.com/
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
8.28%
|
O:
1.14%
H:
0.0%
C:
0.0%
INCY
|
$52.82
0.19%
0.19%
1.8M
|
Health Technology
|
-32.57%
|
O:
0.33%
H:
0.29%
C:
0.01%
jakavi
treatment
disease
positive
chmp
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published:
2022-03-25
(Crawled : 12:20)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
8.28%
|
O:
1.14%
H:
0.0%
C:
0.0%
kymriah
novartis
europe
car-t
positive
therapy
chmp
t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published:
2022-03-25
(Crawled : 12:20)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
8.28%
|
O:
1.14%
H:
0.0%
C:
0.0%
jakavi
novartis
disease
positive
chmp
Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
Published:
2021-10-11
(Crawled : 08:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
11.94%
|
O:
-0.72%
H:
0.0%
C:
0.0%
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
12.5%
|
O:
0.16%
H:
0.19%
C:
-0.64%
acquisition
antibiotics
iot
positive
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
Published:
2021-09-16
(Crawled : 23:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
10.31%
|
O:
-0.63%
H:
0.0%
C:
0.0%
prostate cancer
positive
therapy
cancer
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2
Published:
2021-07-08
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
1.24%
|
O:
0.12%
H:
0.41%
C:
0.33%
positive
molecular
ensovibep
sars-cov-2
in vitro
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Published:
2021-06-02
(Crawled : 06:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
5.63%
|
O:
0.85%
H:
0.37%
C:
0.02%
treatment
potential
positive
results
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Published:
2021-03-23
(Crawled : 07:00)
- globenewswire.com
NVS
|
$92.57
-0.55%
0.0%
910K
|
Health Technology
|
7.59%
|
O:
-0.35%
H:
0.95%
C:
0.06%
prostate cancer
positive
therapy
cancer
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.